Literature DB >> 27987594

Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions.

Sang Hoon Lee1, Ji Yeon Sung2, Dongeun Yong2, Jongsik Chun3, Song Yee Kim4, Joo Han Song4, Kyung Soo Chung4, Eun Young Kim4, Ji Ye Jung4, Young Ae Kang4, Young Sam Kim4, Se Kyu Kim4, Joon Chang4, Moo Suk Park5.   

Abstract

OBJECTIVES: Disruption in the stability of respiratory microbiota is known to be associated with many chronic respiratory diseases. However, only few studies have examined microbiomes in lung cancer. Therefore, we characterized and compared the microbiomes of patients with lung cancer and those with benign mass-like lesions.
MATERIALS AND METHODS: Bronchoalveolar fluid was collected prospectively to evaluate lung masses in patients who had undergone bronchoscopies from May to September 2015. Twenty-eight patients (20 male, 8 female) were enrolled: 20 diagnosed with lung cancer and 8 diagnosed with benign diseases. Samples were analysed by 16S rRNA-based next-generation sequencing.
RESULTS: The participants' mean age was 64±11years. Bacterial operational taxonomic units were classified into 26 phyla, 44 classes, 81 orders, 153 families, 288 genera, and 797 species. The relative abundance of two phyla (Firmicutes and TM7) was significantly increased in patients with lung cancer (p=0.037 and 0.035, respectively). Furthermore, two genera (Veillonella and Megasphaera) were relatively more abundant in lung cancer patients (p=0.003 and 0.022, respectively). The area under the curve of a combination of these two genera used to predict lung cancer was 0.888 (sensitivity=95.0%, specificity=75.0% and sensitivity=70.0%, specificity=100.0%; p=0.002).
CONCLUSION: The results indicate that differences exist in the bacterial communities of patients with lung cancer and those with benign mass-like lesions. The genera Veillonella and Megasphaera showed the potential to serve as biomarkers to predict lung cancer. Thus, the lung microbiota may change the environment in patients with lung cancer.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Benign mass; Bronchoalveolar fluid; Lung cancer; Microbiome; New generation sequencing

Mesh:

Substances:

Year:  2016        PMID: 27987594     DOI: 10.1016/j.lungcan.2016.10.016

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  76 in total

1.  Alterations of fecal bacterial communities in patients with lung cancer.

Authors:  Wei-Quan Zhang; Shu-Kang Zhao; Jun-Wen Luo; Xiao-Peng Dong; Ying-Tao Hao; Hui Li; Lei Shan; Yong Zhou; Hu-Bo Shi; Zai-Yun Zhang; Chuan-Liang Peng; Xiao-Gang Zhao
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

Review 2.  Lung inflammation and disease: A perspective on microbial homeostasis and metabolism.

Authors:  Roberto Mendez; Sulagna Banerjee; Sanjoy K Bhattacharya; Santanu Banerjee
Journal:  IUBMB Life       Date:  2018-11-22       Impact factor: 3.885

Review 3.  When human cells meet bacteria: precision medicine for cancers using the microbiota.

Authors:  Han Zhang; Litao Sun
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

4.  The Microbiome in Lung Cancer Tissue and Recurrence-Free Survival.

Authors:  Brandilyn A Peters; Richard B Hayes; Chandra Goparaju; Christopher Reid; Harvey I Pass; Jiyoung Ahn
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-02-07       Impact factor: 4.254

Review 5.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

6.  Overview of Lung Cancer Immunotherapy.

Authors:  Miguel F Sanmamed; Iñaki Eguren-Santamaria; Kurt A Schalper
Journal:  Cancer J       Date:  2020 Nov/Dec       Impact factor: 3.360

7.  The characterization of lung microbiome in lung cancer patients with different clinicopathology.

Authors:  Danhui Huang; Xiaofang Su; Man Yuan; Shujia Zhang; Jing He; Qiuhua Deng; Wenjun Qiu; Hangming Dong; Shaoxi Cai
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 8.  The microbiome and lung cancer.

Authors:  Abhiram Maddi; Amarpreet Sabharwal; Timothy Violante; Sunita Manuballa; Robert Genco; Santosh Patnaik; Sai Yendamuri
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

9.  Specific gut microbiome signature predicts the early-stage lung cancer.

Authors:  Yajuan Zheng; Zhaoyuan Fang; Yun Xue; Jian Zhang; Junjie Zhu; Renyuan Gao; Shun Yao; Yi Ye; Shihui Wang; Changdong Lin; Shiyang Chen; Hsinyi Huang; Liang Hu; Ge-Ning Jiang; Huanlong Qin; Peng Zhang; Jianfeng Chen; Hongbin Ji
Journal:  Gut Microbes       Date:  2020-04-02

10.  Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer.

Authors:  Jun-Chieh J Tsay; Benjamin G Wu; Michelle H Badri; Jose C Clemente; Nan Shen; Peter Meyn; Yonghua Li; Ting-An Yie; Tenzin Lhakhang; Evan Olsen; Vivek Murthy; Gaetane Michaud; Imran Sulaiman; Aristotelis Tsirigos; Adriana Heguy; Harvey Pass; Michael D Weiden; William N Rom; Daniel H Sterman; Richard Bonneau; Martin J Blaser; Leopoldo N Segal
Journal:  Am J Respir Crit Care Med       Date:  2018-11-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.